Patent Number: 6,251,391

Title: Compositions containing dipepitidyl peptidase IV and tyrosinase or phenylalaninase for reducing opioid-related symptons

Abstract: Compositions and methods are provided to reduce opioid-related symptoms in a human patient of an exorphin selected from the group consisting of a gluteomorphin and a caseomorphin, comprising a physiologically effective amount of a purified casomorphin inhibitor selected from the group consisting of a casomorphinase and a casomorphin ligand, a physiologically effective amount of a purified gluteomorphin inhibitor selected from the group consisting of a gluteomorphinase and a gluteomorphin ligand, and at least one of the group consisting of a physiologically acceptable carrier, adjuvant, excipient, buffer and diluent. In some embodiments, the compositions and methods further comprise a physiologically effective amount of an enkephalin inhibitor, preferably an enkephalinase, and a physiologically effective amount of an endorphin inhibitor, preferably an endorphinase. Preferrably the caseomorphinase is dipeptidyl peptidase IV and the gluteomorphinase is tyrosinase or phenylalaninase.

Inventors: Wilkinson; Randall Eugene (Yakima, WA), Houston; Devin B. (Forsyth, MO)

Assignee: Klaire Laboratories, Inc.

International Classification: A23L 1/305 (20060101); A61K 38/54 (20060101); A61K 38/43 (20060101); A61K 038/48 (); C12N 009/48 (); C12W 009/62 ()

Expiration Date: 06/26/2018